Michael Aitkenhead
Dr. Michael Aitkenhead is a qualified physician with more than 12 years' experience in the healthcare industry, including five years in clinical medicine and seven years in biopharmaceutical equity research. He was formerly a European pharmaceuticals analyst at the Royal Bank of Scotland in London, and prior to this was a European biotechnology analyst with Piper Jaffray. Aitkenhead received his medical degree from the University of Otago, New Zealand, and subsequently completed a master's degree in business administration at Judge Business School, University of Cambridge.
Recent Quotes
"Major alliances reduce execution risk for MSB's late-stage pipeline."
—
Michael Aitkenhead, Edison Investment Research
(11/26/13)
more >
"Results from CYTR's aldoxorubicin phase 2b trial support a favorable risk/benefit profile versus doxorubicin."
—
Michael Aitkenhead, Edison Investment Research
(11/18/13)
more >
"MSB's acquisition consolidates its position as the leading MSC development company."
—
Michael Aitkenhead, Edison Investment Research
(10/21/13)
more >
"CYTR is well funded to advance clinical development of aldoxorubicin."
—
Michael Aitkenhead, Edison Investment Research
(10/10/13)
more >
"CYTR presented positive preclinical data for aldoxorubicin in glioblastoma multiforme."
—
Michael Aitkenhead, Edison Investment Research
(10/2/13)
more >
"We're optimistic that CYTR's aldoxorubicin will show strong advantages over alternatives."
—
Michael Aitkenhead, Edison Investment Research
(9/3/13)
more >
"CYTR will advance aldoxorubicin into phase 2b for glioblastoma multiforme."
—
Michael Aitkenhead, Edison Investment Research
(7/23/13)
more >
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy."
—
The Life Sciences Report Interview with Michael Aikenhead
(6/13/13)
more >
